Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte ™ Immunotherapy Platform

NATICK& QUINCY, Mass., Oct. 2, 2023 /PRNewswire/ -- Avenge Bio, Inc. ( " Avenge " or the " Company " ), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials